Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
119 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H1 2015', provides an overview of the Gastroesophageal (GE) Junction Carcinomas's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Gastroesophageal (GE) Junction Carcinomas - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Gastroesophageal (GE) Junction Carcinomas and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Gastroesophageal (GE) Junction Carcinomas Overview 8 Therapeutics Development 9 Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview 9 Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis 10 Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies 11 Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies 15 Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development 16 Amgen Inc. 16 Aslan Pharmaceuticals Pte. Ltd. 17 AstraZeneca PLC 18 Basilea Pharmaceutica AG 19 Bristol-Myers Squibb Company 20 Celltrion, Inc. 21 Exelixis, Inc. 22 F. Hoffmann-La Roche Ltd. 23 Gilead Sciences, Inc. 24 Merck & Co., Inc. 25 Merck KGaA 26 Merrimack Pharmaceuticals, Inc. 27 Ono Pharmaceutical Co., Ltd. 28 Taiho Pharmaceutical Co., Ltd. 29 Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Combination Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 (tegafur + gimeracil + oteracil) - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 avelumab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 BAL-101553 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 cabozantinib s-malate - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 DKN-01 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 gefitinib - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 GS-5745 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 ipilimumab - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 MK-2206 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 MM-111 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 nimotuzumab - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 nivolumab - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 pertuzumab - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 SNX-5422 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 trastuzumab biosimilar - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 trebananib - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 varlitinib - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Gastroesophageal (GE) Junction Carcinomas - Recent Pipeline Updates 82 Gastroesophageal (GE) Junction Carcinomas - Dormant Projects 115 Gastroesophageal (GE) Junction Carcinomas - Discontinued Products 116 Gastroesophageal (GE) Junction Carcinomas - Product Development Milestones 117 Featured News & Press Releases 117 Sep 19, 2014: Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on MM-111 at the ESMO 2014 Congress 117 Feb 06, 2012: Aslan Pharma Receives KFDA And IRB Grants Approval To Initiate Phase IIa Study Of ASLAN001 At Seoul National University 117 Appendix 118 Methodology 118 Coverage 118 Secondary Research 118 Primary Research 118 Expert Panel Validation 118 Contact Us 118 Disclaimer 119
List of Tables Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H1 2015 9 Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Comparative Analysis by Late Stage Development, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Amgen Inc., H1 2015 16 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 17 Gastroesophageal (GE) Junction Carcinomas - Pipeline by AstraZeneca PLC, H1 2015 18 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Basilea Pharmaceutica AG, H1 2015 19 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Bristol-Myers Squibb Company, H1 2015 20 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Celltrion, Inc., H1 2015 21 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Exelixis, Inc., H1 2015 22 Gastroesophageal (GE) Junction Carcinomas - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 23 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Gilead Sciences, Inc., H1 2015 24 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck & Co., Inc., H1 2015 25 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck KGaA, H1 2015 26 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 27 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 28 Gastroesophageal (GE) Junction Carcinomas - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 29 Assessment by Monotherapy Products, H1 2015 30 Assessment by Combination Products, H1 2015 31 Number of Products by Stage and Target, H1 2015 33 Number of Products by Stage and Mechanism of Action, H1 2015 35 Number of Products by Stage and Route of Administration, H1 2015 37 Number of Products by Stage and Molecule Type, H1 2015 39 Gastroesophageal (GE) Junction Carcinomas Therapeutics - Recent Pipeline Updates, H1 2015 82 Gastroesophageal (GE) Junction Carcinomas - Dormant Projects, H1 2015 115 Gastroesophageal (GE) Junction Carcinomas - Discontinued Products, H1 2015 116
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
